Immunopathogenesis of myositis

被引:0
作者
Hohlfeld, R [1 ]
机构
[1] MAX PLANCK INST, ABT NEUROIMMUNOL, MARTINSRIED, GERMANY
关键词
dermatomyositis; polymyositis; inclusion body myositis; pathogenesis; CYTOTOXIC T-CELLS; INFLAMMATORY MYOPATHIES; LYMPHOCYTES-T; HUMAN MYOBLASTS; GAMMA; EXPRESSION; MYOTUBES; MUSCLE; RECEPTOR;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
These inflammatory muscular disorders include dermatomyositis (DM), polymyositis (PM) and inclusion body myositis (IBM). One of the characteristic histological features of DM is ''perifascicular atrophy''. Immunohistochemical analyses in DM show deposition of complement proteins in capillaries. The patients probably produce pathological antibodies that react with components of the muscle endothelial cells, thus causing secondary deposition of complement. In contrast, PM is marked by a cellular injury mechanism. The characteristic histological feature is endomysial T cell infiltration, consisting predominantly of CD8-positive T lymphocytes. These cytotoxic T cells surround and invade individual muscle fibres. This culminates in destruction of the muscle fibre. The attacked muscle fibres express class I (HLA-A, B, C) histocompatibility antigens. It is likely that the CD-8 positive T lymphocytes recognise muscular autoantigens as HLA-bound peptides. The active autoantigens are still unknown. In IBM - though not in PM - electron-microscopy reveals intranuclear and intracytoplasmic filaments that resemble myxoviruses. Hence, although it is possible that IBM is based on a virus infection, this has not been proved. Other investigations have shown interesting immunohistochemical similarities between IBM and Alzheimer's disease.
引用
收藏
页码:1 / 3
页数:3
相关论文
共 50 条
[21]   Autoimmune myositis [J].
Walker, UA ;
Ketelsen, UP ;
Peter, HH .
ALLERGOLOGIE, 2000, 23 (04) :171-181
[22]   Exercise in Myositis [J].
Helene Alexanderson .
Current Treatment Options in Rheumatology, 2018, 4 (4) :289-298
[23]   Immunopathogenesis of vitiligo [J].
Sandoval-Cruz, Manuel ;
Garcia-Carrasco, Mario ;
Sanchez-Porras, Renan ;
Mendoza-Pinto, Claudia ;
Jimenez-Hernandez, Mario ;
Munguia-Realpozo, Pamela ;
Ruiz-Argueelles, Alejandro .
AUTOIMMUNITY REVIEWS, 2011, 10 (12) :762-765
[24]   Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits [J].
Dalakas, Marinos C. .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (04) :413-423
[25]   Myositis-specific autoantibodies: an important tool to support diagnosis of myositis [J].
Betteridge, Z. ;
McHugh, N. .
JOURNAL OF INTERNAL MEDICINE, 2016, 280 (01) :8-23
[26]   The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort [J].
Edigin, Ehizogie ;
Hassan, Ahmed S. ;
Mathur, Tanisha ;
Manadan, Augustine .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (08)
[27]   Neues zur Pathogenese der MyositidenNew aspects on the pathogenesis of myositis [J].
B. Stuhlmüller ;
E. Feist ;
T. Häupl ;
G.-R. Burmester ;
N. Pipitone .
Zeitschrift für Rheumatologie, 2013, 72 :209-219
[28]   Inflammatory Muscle Disorders - State of the Art of Diagnosis and Treatment of Myositis [J].
Fitzner, Maren ;
Schmidt, Jens .
PHYSIKALISCHE MEDIZIN REHABILITATIONSMEDIZIN KURORTMEDIZIN, 2017, 27 (01) :23-34
[29]   Therapeutic advances in myositis [J].
Aggarwal, Rohit ;
Oddis, Chester V. .
CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (06) :635-641
[30]   Inclusion Body Myositis [J].
Dimachkie, Mazen M. ;
Barohn, Richard J. .
SEMINARS IN NEUROLOGY, 2012, 32 (03) :237-245